The role of immunotherapy in the prevention of the special treatment complications’ development of the patients with the oral cavity cancer [Text] = Роль імунотерапії в запобіганні розвитку ускладнень спеціального лікування хворих на рак ротової порожнини і ротоглотки / H. Hirna [та ін.] // Клінічна та експериментальна патологія. - 2022. - Т. 21, № 4. - P51-59. - Bibliogr. at the end of the art. MeSH-главная: ИММУНОТЕРАПИЯ -- IMMUNOTHERAPY (использование, методы) РОТОВОЙ ПОЛОСТИ НОВООБРАЗОВАНИЯ -- MOUTH NEOPLASMS (терапия) РОТОГЛОТКИ НОВООБРАЗОВАНИЯ -- OROPHARYNGEAL NEOPLASMS (терапия) Аннотация: The article presents data concerning effectiveness of the immune agent alpha/beta defensins as a accompanying chemotherapy/radiotherapy drug at the 1st stage of treatment of 73 patients with cancer of the oral cavity and oropharynx. The purpose of the work – to evaluate the effectiveness of the immune agent alpha/beta- defensins as a drug, accompanying radiation or chemoradiation therapy, at the 1st stage of treatment of patients with the oral cavity and oropharynx cancer. Materials and methods. Patients of the I and II groups under study received radiation and chemoradiation therapy, respectively, as well as the immune agent alpha/beta defensins 2.0 ml 2 times a day intramuscularly 2 days before the start of the special treatment for 5 days, as well as during the next 10 days of treatment 1 time per day. Patients of III-IV groups, comparative, received similar treatment, but without immunotherapy У статті наведені дані щодо ефективності імунного агента альфа/бета дефензинів, як препарата супроводу хіміо/променевої терапії на 1-му етапі лікування 73 хворих на рак ротової порожнини і ротоглотки Доп.точки доступа: Hirna, H. Rozhko, M. Kostyshyn, I. Tkach, V. Levandovskyi, R. Maltsev, D. Свободных экз. нет